Expression of checkpoint molecules by regulatory T cells in multiple myeloma

In multiple myeloma (MM), the content of T lymphocytes expressing “checkpoint” molecules PD-1, TIM-3, LAG-3, etc. is increased. Regulatory T cells (Treg) can suppress antitumor immune response and play a sufficient role in MM pathogenesis. Like effector T lymphocytes, some Tregs express checkpoint receptors PD-1, TIM-3, etc., however, the biological meaning of such expression, as well as the consequences of blockade of these receptors, are not clear. The significance of type I regulatory T cells (Tr1), which produce the immunosuppressive cytokine interleukin-10, in MM also remains unexplored. The purpose of this work was to study the content of PD-1- and TIM-3-expressing Tregs and Tr1 in patients with MM. The study included 36 patients with MM and 24 matched healthy donors. The content of CD4 + CD25 hi CD127-FoxP3 + Tregs and IL-10-producing CD4 + IL-10 + Tr1 populations expressing PD-1 and TIM-3 was assessed in peripheral blood (PB) and bone marrow (BM) by flow cytometry. The relative content of circulating CD4 + CD25 hi CD127-FoxP3 + Tregs and IL-10-producing CD4 + IL-10 + Tr1 was significantly higher in MM patients compared to healthy donors. A higher relative content of IL-10-producing T lymphocytes was noted compared to Treg. The relative content of Tregs and Tr1 in BM samples did not differ significantly from PB values. The proportion of Tregs expressing PD-1 and TIM-3 in patients with MM did not differ significantly from the values in healthy donors. The content of PD-1- and TIM-3-positive CD4 + IL-10 + T cells was significantly higher in PB samples from MM patients compared to donors. IL-10-producing CD4 + T cells constitute a significant proportion of T lymphocytes in the PB and BM of patients with MM and may play an important role in the pathogenesis of MM. Their content exceeds that of CD4 + CD25 hi CD127-FoxP3 + Treg. A relatively small number of Tregs express the checkpoint receptors PD-1 and TIM-3, no different from donors. The proportion of PD-1-/TIM-3-positive cells is ~20% of CD4 + IL-10 + T cells and significantly exceeds the values of healthy individuals.

Authors

Institutions

Publication Details

Journal
Medical Immunology (Russia)
Published
2024-09-21
DOI
https://doi.org/10.15789/1563-0625-eoc-16849
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Expression of checkpoint molecules by regulatory T cells in multiple myeloma

А. А. Останин, С. А. Сизикова, A. B. Krukovich, Д. С. Баторова
Medical Immunology (Russia)
Multiple Myeloma Research and Treatments
article

Expression of checkpoint molecules by regulatory T cells in multiple myeloma

А. А. Останин, С. А. Сизикова, A. B. Krukovich, Д. С. Баторова
article en

Abstract

In multiple myeloma (MM), the content of T lymphocytes expressing “checkpoint” molecules PD-1, TIM-3, LAG-3, etc. is increased. Regulatory T cells (Treg) can suppress antitumor immune response and play a sufficient role in MM pathogenesis. Like effector T lymphocytes, some Tregs express checkpoint receptors PD-1, TIM-3, etc., however, the biological meaning of such expression, as well as the consequences of blockade of these receptors, are not clear. The significance of type I regulatory T cells (Tr1), which produce the immunosuppressive cytokine interleukin-10, in MM also remains unexplored. The purpose of this work was to study the content of PD-1- and TIM-3-expressing Tregs and Tr1 in patients with MM. The study included 36 patients with MM and 24 matched healthy donors. The content of CD4 + CD25 hi CD127-FoxP3 + Tregs and IL-10-producing CD4 + IL-10 + Tr1 populations expressing PD-1 and TIM-3 was assessed in peripheral blood (PB) and bone marrow (BM) by flow cytometry. The relative content of circulating CD4 + CD25 hi CD127-FoxP3 + Tregs and IL-10-producing CD4 + IL-10 + Tr1 was significantly higher in MM patients compared to healthy donors. A higher relative content of IL-10-producing T lymphocytes was noted compared to Treg. The relative content of Tregs and Tr1 in BM samples did not differ significantly from PB values. The proportion of Tregs expressing PD-1 and TIM-3 in patients with MM did not differ significantly from the values in healthy donors. The content of PD-1- and TIM-3-positive CD4 + IL-10 + T cells was significantly higher in PB samples from MM patients compared to donors. IL-10-producing CD4 + T cells constitute a significant proportion of T lymphocytes in the PB and BM of patients with MM and may play an important role in the pathogenesis of MM. Their content exceeds that of CD4 + CD25 hi CD127-FoxP3 + Treg. A relatively small number of Tregs express the checkpoint receptors PD-1 and TIM-3, no different from donors. The proportion of PD-1-/TIM-3-positive cells is ~20% of CD4 + IL-10 + T cells and significantly exceeds the values of healthy individuals.

Medical Immunology (Russia)Vol. 26(5)
Research Institute of Fundamental and Clinical Immunology (RU)
Openalex Percentile: Top 74%
Multiple Myeloma Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.